As of 2026-10-24, the Intrinsic Value of Novavax Inc (NVAX) is 12.69 USD. This Novavax valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 9.70 USD, the upside of Novavax Inc is 30.80%.
The range of the Intrinsic Value is 7.86 - 33.96 USD
Based on its market price of 9.70 USD and our intrinsic valuation, Novavax Inc (NVAX) is undervalued by 30.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 7.86 - 33.96 | 12.69 | 30.8% |
| DCF (Growth 10y) | 8.41 - 33.23 | 13.04 | 34.4% |
| DCF (EBITDA 5y) | 7.61 - 8.63 | 8.06 | -16.9% |
| DCF (EBITDA 10y) | 8.32 - 10.23 | 9.18 | -5.4% |
| Fair Value | -28.41 - -28.41 | -28.41 | -392.88% |
| P/E | (22.70) - 11.40 | (7.98) | -182.3% |
| EV/EBITDA | (5.25) - 10.94 | 2.45 | -74.7% |
| EPV | (5.68) - (7.73) | (6.71) | -169.1% |
| DDM - Stable | (13.23) - (66.77) | (40.00) | -512.4% |
| DDM - Multi | 5.88 - 23.28 | 9.42 | -2.9% |
| Market Cap (mil) | 2,114.60 |
| Beta | 2.46 |
| Outstanding shares (mil) | 218.00 |
| Enterprise Value (mil) | 2,220.46 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.77% |
| Cost of Debt | 5.68% |
| WACC | 7.56% |